Clinical Trials Centre at the University of the Sunshine Coast (USC) in Australia has launched a clinical trial of a new vaccine for coeliac disease by switching off the immune response of those suffering with the disease to gluten.

Adults aged between 18 and 70 can participate in the trial if they have medically diagnosed the disease and have been following a strict gluten-free diet for one year or more.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
“There is a real unmet need for therapies other than the gluten-free diet for some people with coeliac disease.”

Coeliac disease is a chronic medical condition in which the ingestion of even a small amount of gluten will lead to an immune response that damages the small intestine.

People suffering from the disease struggle with various gastrointestinal symptoms and, if left untreated, the illness can cause potentially serious complications.

Currently, the only way to manage coeliac disease is by strictly avoiding gluten in the diet.

USC Clinical Trials Centre director Lucas Litewka said that the investigational vaccine would be given to trial participants as an injection twice a week for seven weeks.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Litewka further added: “There is a real unmet need for therapies other than the gluten-free diet for some people with coeliac disease. This is a very exciting potential new therapy that has been undergoing clinical trials for several years now.”

The trial of the investigational vaccine will be performed alongside gastroenterologist Dr James Daveson at the centre on Sippy Downs Drive in Sippy Downs.

According to Dr Daveson, the vaccine might potentially restore gluten tolerance in people with coeliac disease.